Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges in acid/peptic disorders: a symposium overview.

H R Clearfield1

  • 1Division of Gastroenterology, Hahnemann University, Philadelphia, Pennsylvania 19102.

Alimentary Pharmacology & Therapeutics
|January 1, 1991
PubMed
Summary

Treatment for peptic ulcer disease has evolved from simple diets to complex pharmacologic strategies. New drugs and regimens offer improved management but also present more complicated treatment decisions for acid/peptic disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consultant strategies for the gastroenterologist.

The American journal of gastroenterology·1999
Same author

Clinical intestinal gas syndromes.

Primary care·1996
Same author

Pharmacologic therapy for inflammatory bowel disease.

American family physician·1995
Same author

Gastrin's trophic effect in the colon: identification of a signaling pathway mediated by protein kinase C.

Peptides·1993
Same author

Management of NSAID-induced ulcer disease.

American family physician·1992
Same author

Azathioprine reduces extravasation and neutrophil trafficking in immune complex-mediated inflammation in the rat colon.

Agents and actions·1991

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Internal Medicine

Background:

  • Peptic ulcer disease (PUD) treatment before 1977 relied on diet, antacids, and anticholinergics, with significant therapeutic controversies.
  • The advent of H2-receptor antagonists aimed to simplify PUD management, proving effective for many acid/peptic disorders.
  • Despite advancements, specific patient subsets like those with recurrent ulcers, NSAID-induced ulcers, stress ulcers, or refractory esophagitis pose ongoing challenges.

Purpose of the Study:

  • To review the pathophysiology of acid/peptic disorders.
  • To evaluate the role of pharmacologic agents in PUD and reflux esophagitis treatment.
  • To outline clinically applicable treatment strategies for complex cases.

Main Methods:

  • A Transatlantic Conference convened experts from the UK, US, and Canada in January 1990.

Related Experiment Videos

  • The conference reviewed current knowledge on acid/peptic disorders and therapeutic interventions.
  • Discussions focused on five key areas: acid suppression, NSAID-induced ulcers, stress ulcers, and treatment controversies.

    • Main Results:

    • H2-receptor antagonists are effective, but new regimens like maintenance therapy and nocturnal dosing are indicated for PUD.
    • Novel drugs including sucralfate, misoprostol, and omeprazole offer diverse mechanisms of action.
    • While understanding of PUD pathogenesis has grown, treatment decisions have become more complex.

    Conclusions:

    • The management of peptic ulcer disease and related acid/peptic disorders requires sophisticated pharmacologic approaches.
    • Addressing complex patient subsets necessitates tailored treatment strategies beyond standard therapies.
    • Continued research and clinical evaluation are crucial for optimizing PUD and reflux esophagitis management.